Skip to main content
SpringerLink
Log in

FDA and EMA decisions on Avastin use in breast cancer

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. U.S. Food and Drug Administration.FDA Begins Process To Remove Breast Cancer Indication From Avastin Label. Media Release: 17 Dec 2010. Available from: URL: http://www.fda.gov

  2. European Medicines Agency.European Medicines Agency completes its review of Avastin used in breast cancer treatment. Media Release: 16 Dec 2010. Available from: URL: http://www.ema.europa.eu

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

FDA and EMA decisions on Avastin use in breast cancer. React. Wkly. 1333, 2 (2011). https://doi.org/10.2165/00128415-201113330-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201113330-00004

Keywords

Search

Navigation